Europe Oncolytic Virus Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Oncolytic Virus Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 HSV-based Oncolytic Viruses Market Performance (Volume)
  • 2.1.2 Adenoviruses-based Oncolytic Viruses Market Performance (Volume)
  • 2.1.3 Vaccinia Virus-based Oncolytic Viruses Market Performance (Volume)
  • 2.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses Market Performance (Volume)
  • 2.1.5 Newcastle Disease Virus-based Oncolytic Viruses Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 HSV-based Oncolytic Viruses Market Performance (Value)
  • 2.1.2 Adenoviruses-based Oncolytic Viruses Market Performance (Value)
  • 2.1.3 Vaccinia Virus-based Oncolytic Viruses Market Performance (Value)
  • 2.1.4 Vesicular Stomatitis Virus-based Oncolytic Viruses Market Performance (Value)
  • 2.1.5 Newcastle Disease Virus-based Oncolytic Viruses Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Pharmaceutical Market Performance (Volume)
  • 3.1.2 Health Care Market Performance (Volume)
  • 3.1.3 Commerical Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Merck
  • 4.1.1 Merck Profiles
  • 4.1.2 Merck Product Information
  • 4.1.3 Merck Oncolytic Virus Business Performance
  • 4.1.4 Merck Oncolytic Virus Business Development and Market Status
• 4.2 Otsuka Pharmaceutical Co
  • 4.2.1 Otsuka Pharmaceutical Co Profiles
  • 4.2.2 Otsuka Pharmaceutical Co Product Information
  • 4.2.3 Otsuka Pharmaceutical Co Oncolytic Virus Business Performance
  • 4.2.4 Otsuka Pharmaceutical Co Oncolytic Virus Business Development and Market Status
• 4.3 Pfizer
  • 4.3.1 Pfizer Profiles
  • 4.3.2 Pfizer Product Information
  • 4.3.3 Pfizer Oncolytic Virus Business Performance
  • 4.3.4 Pfizer Oncolytic Virus Business Development and Market Status
• 4.4 Roche
  • 4.4.1 Roche Profiles
  • 4.4.2 Roche Product Information
  • 4.4.3 Roche Oncolytic Virus Business Performance
  • 4.4.4 Roche Oncolytic Virus Business Development and Market Status
• 4.5 Cold Genesys
  • 4.5.1 Cold Genesys Profiles
  • 4.5.2 Cold Genesys Product Information
  • 4.5.3 Cold Genesys Oncolytic Virus Business Performance
  • 4.5.4 Cold Genesys Oncolytic Virus Business Development and Market Status
• 4.6 Genelux
  • 4.6.1 Genelux Profiles
  • 4.6.2 Genelux Product Information
  • 4.6.3 Genelux Oncolytic Virus Business Performance
  • 4.6.4 Genelux Oncolytic Virus Business Development and Market Status
• 4.7 Latima
  • 4.7.1 Latima Profiles
  • 4.7.2 Latima Product Information
  • 4.7.3 Latima Oncolytic Virus Business Performance
  • 4.7.4 Latima Oncolytic Virus Business Development and Market Status
• 4.8 Neotropix
  • 4.8.1 Neotropix Profiles
  • 4.8.2 Neotropix Product Information
  • 4.8.3 Neotropix Oncolytic Virus Business Performance
  • 4.8.4 Neotropix Oncolytic Virus Business Development and Market Status
• 4.9 Shanghai Sunway Biotech
  • 4.9.1 Shanghai Sunway Biotech Profiles
  • 4.9.2 Shanghai Sunway Biotech Product Information
  • 4.9.3 Shanghai Sunway Biotech Oncolytic Virus Business Performance
  • 4.9.4 Shanghai Sunway Biotech Oncolytic Virus Business Development and Market Status
• 4.10 SillaJen
  • 4.10.1 SillaJen Profiles
  • 4.10.2 SillaJen Product Information
  • 4.10.3 SillaJen Oncolytic Virus Business Performance
  • 4.10.4 SillaJen Oncolytic Virus Business Development and Market Status
• 4.11 Takara Bio
• 4.12 Theravir

5 Market Performance for Manufacturers

• 5.1 Europe Oncolytic Virus Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Europe Oncolytic Virus Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Europe Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Europe Oncolytic Virus Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Germany Market Performance for Manufacturers
  • 6.1.1 Germany Oncolytic Virus Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Germany Oncolytic Virus Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Germany Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Germany Oncolytic Virus Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 UK Market Performance for Manufacturers
  • 6.2.1 UK Oncolytic Virus Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 UK Oncolytic Virus Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 UK Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 UK Oncolytic Virus Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 France Market Performance for Manufacturers
  • 6.3.1 France Oncolytic Virus Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 France Oncolytic Virus Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 France Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 France Oncolytic Virus Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Russia Market Performance for Manufacturers
  • 6.4.1 Russia Oncolytic Virus Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Russia Oncolytic Virus Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Russia Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Russia Oncolytic Virus Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Benelux Market Performance for Manufacturers
  • 6.5.1 Benelux Oncolytic Virus Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Benelux Oncolytic Virus Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Benelux Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Benelux Oncolytic Virus Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Italy Market Performance for Manufacturers
  • 6.6.1 Italy Oncolytic Virus Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Italy Oncolytic Virus Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Italy Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Italy Oncolytic Virus Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Spain Market Performance for Manufacturers
  • 6.7.1 Spain Oncolytic Virus Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Spain Oncolytic Virus Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Spain Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Spain Oncolytic Virus Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Oncolytic Virus Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Oncolytic Virus Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Oncolytic Virus Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Oncolytic Virus Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Europe Oncolytic Virus Market Performance (Sales Point)

• 7.1 Europe Oncolytic Virus Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Europe Oncolytic Virus Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Europe Oncolytic Virus Price (USD/Unit) by Regions 2013-2018
• 7.4 Europe Oncolytic Virus Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Europe Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Germany Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 UK Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 France Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Russia Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Benelux Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Italy Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Oncolytic Virus Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Pharmaceutical Industry
• 11.2 Health Care Industry
• 11.3 Commerical Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Europe Oncolytic Virus Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Europe Oncolytic Virus Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Germany Oncolytic Virus Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 UK Oncolytic Virus Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 France Oncolytic Virus Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Russia Oncolytic Virus Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Benelux Oncolytic Virus Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Italy Oncolytic Virus Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Spain Oncolytic Virus Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 HSV-based Oncolytic Viruses Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Adenoviruses-based Oncolytic Viruses Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.4 Vaccinia Virus-based Oncolytic Viruses Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.5 Vesicular Stomatitis Virus-based Oncolytic Viruses Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Pharmaceutical Sales and and Growth Rate 2019-2024
  • 12.4.3 Health Care Sales and and Growth Rate 2019-2024
  • 12.4.4 Commerical Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Europe Oncolytic Virus Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Europe Oncolytic Virus Gross Profit Trend 2019-2024

13 Conclusion